Option chain shows key data for RBAZ Bancorp's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for RBAZ Bancorp.

RBAZ Bancorp (OTC:RBAZ) Stock, Option Chain

RBAZ Bancorp Inc is a full service, community bank providing deposit and loan products and convenient, on-line and mobile banking to individuals, businesses and professionals.

RBAZ Bancorp Inc

Earnings

News

ABEV

Ambev Q4 Net Revenue R$27,035M, Up 35.2% YoY; EPS R$0.31, Up From R$0.29 YoY

ADEA

Adeia Extends Multi-Year IP License Agreement With SK Broadband To Enhance IPTV Services

<p>Needham  analyst Ami Fadia   reiterates Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and maintains $32 price target.</p>


Price Target

Reiteration

Analyst Ratings

DAWN

Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $32 Price Target

<p>FTAI believes this debt financing will provide the SCI the ability to deploy $4.0+ billion of total capital into on-lease 737NG and A320ceo aircraft while allowing FTAI to maintain an asset-light business model. All engines owned by the SCI will be powered exclusively via engine and module exchanges with FTAI's Maintenance, Repair and Exchange ("MRE") business.</p>


FTAI

FTAI Aviation Announced Its Strategic Capital Initiative Has Obtained A Commitment For $2.5B Of Asset-level Debt Financing Led By Global Investment Firm Atlas SP Partners

<p><strong>First Quarter and Full Year 2025 Guidance</strong></p>
<p>For the First Quarter and Full Year 2025, the Company currently expects (dollars in millions):</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure><figure class="table"><br />
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="2"><strong>Q1 2025Guidance</strong></td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="2"><strong>FY 2025Guidance</strong></td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="6"><strong>Unaudited</strong></td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="6">(dollars in millions)</td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>Revenues</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$407 - $427</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$1,838 - $1,888</td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>Gross profit</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$109 - $115</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$536 - $552</td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>ex-TAC Gross Profit&#x2A;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$142 - $148</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$674 - $690</td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA&#x2A;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$22 - $26</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$201 - $209</td>
<td colspan="1">&nbsp;</td>
</tr>
<tr>
<td>Non-GAAP Net Income (Loss)&#x2A;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$2 - $6</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">&nbsp;</td>
<td colspan="1">$122 - $128</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><br />&nbsp;</p>


Guidance

TBLA

Taboola.com Expects Q1 Revenue Of $407M-$427M Vs $455.85M Est, FY25 Revenue Of $1.838B-$1.888B Vs $2.03B Est

WIIM

INTU

Intuit shares are trading higher after the company reported better-than-expected Q2 financial results.

<p>Needham  analyst Ami Fadia   maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $205 to $210.</p>


JAZZ

Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $210

WDAY

Workday shares are trading higher after the company reported better-than-expected Q4 financial results.

<p>Citigroup  analyst Joanne Wuensch   reinstates Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) with a Buy and announces $450 price target.</p>


Initiation

Citigroup Reinstates Buy on Stryker, Announces $450 Price Target

WKSP

Worksport Says Dealer Network Has Expanded By 30% In The First Two Months Of 2025; Company Also Debuts AL4 Premium Tonneau Cover On E-Commerce Platform

ENVB

Enveric Biosciences shares are trading higher after the company announced its non-hallucinogenic psychedelic compounds showed promise for treating addiction and ADHD.

<p>Needham  analyst Mike Matson   reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from Hold to Hold.</p>


MASI

Needham Reiterates Hold on Masimoto Hold

Buybacks

Taboola Expands Share Repurchase Authorization By Up To $200M

INVX

Innovex International shares are trading higher. The company reported Q4 financial results.

Earnings Beats

Clear Secure Q4 2024 Adj. EPS $0.90 Beats $0.29 Estimate, Sales $206.270M Beat $202.147M Estimate

SMCI

Super Micro Computer shares are trading higher after the company filed its quarterly report.

SCCO

Shares of copper stocks are trading higher after President Trump reportedly ordered a new tariff probe into US copper imports.

<p>Needham  analyst Ami Fadia   reiterates Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Buy and maintains $50 price target.</p>


HRMY

Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target

Taboola.com Q4 2024 Adj. EPS $0.21 Beats $0.15 Estimate

Global Net Lease Approved Share Repurchase Program Authorizing The Company To Opportunistically Repurchase Up To $300M Of Its Outstanding Common Stock

RBAZ Bancorp

Comments

RBAZ Bancorp

RBAZ Bancorp (RBAZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga